Targeting SRC and Epidermal Growth Factor Receptor in Colorectal Cancer: Rationale and Progress into the Clinic

Overview

Journal Gastrointest Cancer Res

Date 2009 Apr 11

PMID 19360146

Citations 15

Authors

Scott Kopetz

Affiliations

Soon will be listed here.

Abstract

Src is a non-receptor protein tyrosine kinase that affects proliferation, angiogenesis, differentiation, migration, invasion, and regulation of apoptosis in colorectal cancer cells. Src activation is a frequent early epigenetic event in colorectal cancer, and is progressively increased in metastatic tumors as compared with primary tumors. Src has also been implicated as a component of epidermal growth factor receptor (EGFR) signal transduction. In particular, Src, as a mediator of receptor transactivation, can uniquely activate EGFR in the absence of EGFR ligand, and a Src inhibitor is synergistic with an EGFR monoclonal antibody in vitro in eliciting growth inhibition. Src inhibition is also synergistic in vivo with platinum chemotherapeutics, further increasing the potential of combination regimens with Src inhibitors. The current Src inhibitors in clinical trials are reviewed.

Citing Articles

A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF colorectal tumors.

Ruiz-Saenz A, Atreya C, Wang C, Pan B, Dreyer C, Brunen D Nat Cancer. 2023; 4(2):240-256.

PMID: 36759733 PMC: 9970872. DOI: 10.1038/s43018-022-00508-5.

Rapid Actions of the Nuclear Progesterone Receptor through cSrc in Cancer.

Bello-Alvarez C, Zamora-Sanchez C, Camacho-Arroyo I Cells. 2022; 11(12).

PMID: 35741094 PMC: 9221966. DOI: 10.3390/cells11121964.

Identification of Synergistic Drug Combinations to Target KRAS-Driven Chemoradioresistant Cancers Utilizing Tumoroid Models of Colorectal Adenocarcinoma and Recurrent Glioblastoma.

Gupta K, Jones J, de Araujo Farias V, Mackeyev Y, Singh P, Quinones-Hinojosa A Front Oncol. 2022; 12:840241.

PMID: 35664781 PMC: 9158132. DOI: 10.3389/fonc.2022.840241.

Piperine Attenuates Lithocholic Acid-Stimulated Interleukin-8 by Suppressing Src/EGFR and Reactive Oxygen Species in Human Colorectal Cancer Cells.

Li S, Nguyen T, Ung T, Sah D, Park S, Lakshmanan V Antioxidants (Basel). 2022; 11(3).

PMID: 35326180 PMC: 8944659. DOI: 10.3390/antiox11030530.

Interleukin-1β Induces Tissue Factor Expression in A549 Cells via EGFR-Dependent and -Independent Mechanisms.

Mechelke T, Wittig F, Ramer R, Hinz B Int J Mol Sci. 2021; 22(12).

PMID: 34205482 PMC: 8235322. DOI: 10.3390/ijms22126606.

References

Trevino J, Summy J, Lesslie D, Parikh N, Hong D, Lee F . Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol. 2006; 168(3):962-72. PMC: 1606527. DOI: 10.2353/ajpath.2006.050570. View

Ahn S, Kim J, Lucaveche C, Reedy M, Luttrell L, Lefkowitz R . Src-dependent tyrosine phosphorylation regulates dynamin self-assembly and ligand-induced endocytosis of the epidermal growth factor receptor. J Biol Chem. 2002; 277(29):26642-51. DOI: 10.1074/jbc.M201499200. View

Pleiman C, Hertz W, Cambier J . Activation of phosphatidylinositol-3' kinase by Src-family kinase SH3 binding to the p85 subunit. Science. 1994; 263(5153):1609-12. DOI: 10.1126/science.8128248. View

Bao J, Gur G, Yarden Y . Src promotes destruction of c-Cbl: implications for oncogenic synergy between Src and growth factor receptors. Proc Natl Acad Sci U S A. 2003; 100(5):2438-43. PMC: 151359. DOI: 10.1073/pnas.0437945100. View

Camp E, Summy J, Bauer T, Liu W, Gallick G, Ellis L . Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res. 2005; 11(1):397-405. View

Castoria G, Migliaccio A, Bilancio A, Di Domenico M, De Falco A, Lombardi M . PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J. 2001; 20(21):6050-9. PMC: 125704. DOI: 10.1093/emboj/20.21.6050. View

Lee D, Gautschi O . Clinical development of SRC tyrosine kinase inhibitors in lung cancer. Clin Lung Cancer. 2006; 7(6):381-4. DOI: 10.3816/clc.2006.n.020. View

Daub H, Weiss F, Wallasch C, Ullrich A . Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature. 1996; 379(6565):557-60. DOI: 10.1038/379557a0. View

Termuhlen P, Curley S, Talamonti M, Saboorian M, Gallick G . Site-specific differences in pp60c-src activity in human colorectal metastases. J Surg Res. 1993; 54(4):293-8. DOI: 10.1006/jsre.1993.1046. View

10.

Ellis L, Staley C, Liu W, Fleming R, Parikh N, Bucana C . Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J Biol Chem. 1998; 273(2):1052-7. DOI: 10.1074/jbc.273.2.1052. View

11.

Roche S, Koegl M, Barone M, Roussel M, Courtneidge S . DNA synthesis induced by some but not all growth factors requires Src family protein tyrosine kinases. Mol Cell Biol. 1995; 15(2):1102-9. PMC: 232016. DOI: 10.1128/MCB.15.2.1102. View

12.

Maa M, Leu T, McCarley D, Schatzman R, Parsons S . Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. Proc Natl Acad Sci U S A. 1995; 92(15):6981-5. PMC: 41455. DOI: 10.1073/pnas.92.15.6981. View

13.

Cursi S, Rufini A, Stagni V, Condo I, Matafora V, Bachi A . Src kinase phosphorylates Caspase-8 on Tyr380: a novel mechanism of apoptosis suppression. EMBO J. 2006; 25(9):1895-905. PMC: 1456929. DOI: 10.1038/sj.emboj.7601085. View

14.

Luttrell L, Ferguson S, Daaka Y, Miller W, Maudsley S, Della Rocca G . Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science. 1999; 283(5402):655-61. DOI: 10.1126/science.283.5402.655. View

15.

Griffiths G, Koh M, Brunton V, Cawthorne C, Reeves N, Greaves M . Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis. J Biol Chem. 2004; 279(44):46113-21. DOI: 10.1074/jbc.M408550200. View

16.

Summy J, Gallick G . Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res. 2006; 12(5):1398-401. DOI: 10.1158/1078-0432.CCR-05-2692. View

17.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

18.

Wilson L, Luttrell D, Parsons J, Parsons S . pp60c-src tyrosine kinase, myristylation, and modulatory domains are required for enhanced mitogenic responsiveness to epidermal growth factor seen in cells overexpressing c-src. Mol Cell Biol. 1989; 9(4):1536-44. PMC: 362570. DOI: 10.1128/mcb.9.4.1536-1544.1989. View

19.

Hirsch C, Smith-Windsor E, Bonham K . Src family kinase members have a common response to histone deacetylase inhibitors in human colon cancer cells. Int J Cancer. 2005; 118(3):547-54. DOI: 10.1002/ijc.21383. View

20.

Bromberg J, Horvath C, Besser D, Lathem W, Darnell Jr J . Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol. 1998; 18(5):2553-8. PMC: 110635. DOI: 10.1128/MCB.18.5.2553. View